2 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Recruiting 2 |
Follow Newly Diagnosed: new trials by email Literature Review of Newly Diagnosed trials Research Report on Newly Diagnosed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 59 | 2024-06-12 | 2025-06-12 |
| Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). daunomycin/Idarubicin+ Silybinin, daunomycin/Idarubicin - Acute Myeloid Leukemia, Newly Diagnosed | Phase 4 | Recruiting | Fujian Medical University Union Hospital | 100 | 2022-04-01 | 2026-05-01 |
Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Myeloid (1) · Lymphoproliferative Disorders (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1)
Daunorubicin (1) · Dexamethasone (1) · Idarubicin (1) · Lenalidomide (1) · carfilzomib (1) · daratumumab (1)
Fujian Medical University Union Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (2)